Drugs / taprenepag isopropyl
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00934089 | Jan → Jun 2010 | ocular hypertension, open-angle glaucoma | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00572455 | Dec 2007 → Jun 2009 | ocular hypertension, open-angle glaucoma | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | taprenepag isopropyl | “A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329)” PMID 21851167 ↗ Sep 2011 |
| Known as | PF-04217329 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00934089 ↗ |
| Action | Activate | “a selective EP(2) receptor agonist” PMID 21851167 ↗ Sep 20111“Prostanoid EP2 receptor agonist” CHEMBL2105692 ↗ |
| Modality | Small molecule | — CHEMBL2105692 ↗ |
| Route | Topical | “administered as a topical ophthalmic solution” PMID 21851167 ↗ Sep 2011 |
| Target | PTGER2 | “Prostanoid EP2 receptor agonist” CHEMBL2105692 ↗ |